Berry-Kravis E - Search Results

1

Emerging pharmacological therapies in fragile X syndrome and autism.

Yamasue H, Aran A, Berry-Kravis E. Yamasue H, et al. Curr Opin Neurol. 2019 Aug;32(4):635-640. doi: 10.1097/WCO.0000000000000703. Curr Opin Neurol. 2019. PMID: 31045620 Review.

2

Cyclic AMP metabolism in fragile X syndrome.

Berry-Kravis E, Huttenlocher PR. Berry-Kravis E, et al. Ann Neurol. 1992 Jan;31(1):22-6. doi: 10.1002/ana.410310105. Ann Neurol. 1992. PMID: 1371909

3

Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome.

Berry-Kravis E, Sklena P. Berry-Kravis E, et al. Am J Med Genet. 1993 Jan 1;45(1):81-7. doi: 10.1002/ajmg.1320450120. Am J Med Genet. 1993. PMID: 8380312

4

Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation.

Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. Berry-Kravis E, et al. Ann Neurol. 2005 Jan;57(1):144-7. doi: 10.1002/ana.20360. Ann Neurol. 2005. PMID: 15622531

5

Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS).

Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA. Hall DA, et al. Neurology. 2005 Jul 26;65(2):299-301. doi: 10.1212/01.wnl.0000168900.86323.9c. Neurology. 2005. PMID: 16043804

6

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R. Berry-Kravis E, et al. J Child Adolesc Psychopharmacol. 2006 Oct;16(5):525-40. doi: 10.1089/cap.2006.16.525. J Child Adolesc Psychopharmacol. 2006. PMID: 17069542 Clinical Trial.

7

Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines.

Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Berry-Kravis E, et al. Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140. doi: 10.1002/mds.21493. Mov Disord. 2007. PMID: 17618523 Review.

8

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.

Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT. Berry-Kravis E, et al. J Dev Behav Pediatr. 2008 Aug;29(4):293-302. doi: 10.1097/DBP.0b013e31817dc447. J Dev Behav Pediatr. 2008. PMID: 18698192 Clinical Trial.

9

Fragile X: leading the way for targeted treatments in autism.

Wang LW, Berry-Kravis E, Hagerman RJ. Wang LW, et al. Neurotherapeutics. 2010 Jul;7(3):264-74. doi: 10.1016/j.nurt.2010.05.005. Neurotherapeutics. 2010. PMID: 20643379 Free PMC article. Review.

10

Autonomic regulation in fragile X syndrome.

Heilman KJ, Harden ER, Zageris DM, Berry-Kravis E, Porges SW. Heilman KJ, et al. Dev Psychobiol. 2011 Dec;53(8):785-95. doi: 10.1002/dev.20551. Epub 2011 May 5. Dev Psychobiol. 2011. PMID: 21547900 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

348 results

Search Page